Actualités

Lilly is trying to protect an experimental obesity medicine from unauthorized sellers before regulators decide whether to approve it.

Lilly said the products being sold on the black market are unverified, unapproved, and not worth the risk.

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

Dismissal removes one legal challenge involving compounded alternatives while Novo confronts intensifying commercial competition in obesity treatments.

A Texas judge dismissed claims that the drugmakers illegally blocked access to compounded weight-loss drugs.

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.

Novo alleges that Lilly’s Zepbound advertisements compare the drug’s highest approved dose with lower doses of Wegovy.

Eli Lilly and Company (LLY) on Tuesday received traditional approval from the US Food and Drug Admin

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

Baxfendy gained FDA clearance for uncontrolled hypertension patients as AstraZeneca expands its cardiovascular and metabolic portfolio.